In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria.
AUTOR(ES)
Schülin, T
RESUMO
The comparative in vitro activity of RU 64004 (also known as HMR 3004), a new ketolide antibiotic, was tested by agar dilution against approximately 500 gram-positive organisms, including multiply resistant enterococci, streptococci, and staphylococci. All streptococci were inhibited by < or = 1 microg of RU 64004 per ml. The ketolide was more potent than other macrolides against erythromycin A-susceptible staphylococci and was generally more potent than clindamycin against erythromycin A-resistant strains susceptible to this agent. Clindamycin-resistant staphylococci (MIC, > 128 microg/ml) proved resistant to the ketolide, but some erythromycin A- and clindamycin-resistant enterococci remained susceptible to RU 64004.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=163882Documentos Relacionados
- In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria.
- In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.
- In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients with cancer.
- In vitro activity of U-57930E, a new clindamycin analog, against aerobic gram-positive bacteria.
- Activity of glycopeptides against vancomycin-resistant gram-positive bacteria.
